Unlocking the Potential of ND3 as a Drug Target and Biomarker

Target Name: ND3

NCBI ID: G4537

Content of Review Report on ND3 Target / Biomarker

ND3

Unlocking the Potential of ND3 as a Drug Target and Biomarker

Introduction

NADH dehydrogenase 3 (ND3) is a mitochondrial enzyme involved in the electron transport chain, which is a critical process for the production of ATP energy in cells. ND3 has been identified as a potential drug target and biomarker due to its unique structure, function, and expression pattern in various tissues.In this article, we will explore the potential of ND3 as a drug target and biomarker, and discuss the current research on its expression and potential clinical applications.

The Role of ND3 in the Electron Transport Chain

The electron transport chain is a complex series of proteins that transfer electrons from the ubiquin protein to ubiquitin protein, ultimately producing ATP energy. ND3 is one of the key enzymes in this chain, responsible for the transfer of electrons from ubiquitin Q to ubiquitin Factor F2. This process is critical for the production of ATP energy, which is the primary source of energy for most cellular processes.

ND3 is a 26 kDa protein that consists of 166 amino acids. It has a unique structure, with a single catalytic active site and a long extracellular loop. ND3 is expressed in various tissues, including heart, skeletal muscles, liver, and kidney. It is also highly co-expressed with other genes involved in the electron transport chain, such as NAD+-dependent transmembrane proteins (NAD+-TMs) and mitochondrial DNA.

Expression and Localization of ND3

ND3 is a highly expressed protein, with higher levels of expression in the liver and heart compared to other tissues. In the liver, ND3 is found in the mitochondrial outer membrane (MOM), the inner membrane (IMM), and in the cytoplasm. In the heart, it is found in the intercalated discs, the intima, and in the cytoplasm. ND3 is also expressed in various tissues and cells involved in the electron transport chain, such as muscle fibers, red blood cells, and the gut epithelium.

ND3's Expression Pattern and Its Potential as a Drug Target

The expression pattern of ND3 is highly consistent across various tissues and cells, which suggests its relevance as a drug target. Studies have shown that ND3 is often overexpressed in various diseases, including cancer, cardiovascular disease, and neurological disorders.

For example, ND3 has been shown to be overexpressed in various types of cancer, such as breast, ovarian, and colorectal cancer. This overexpression is associated with increased nuclear translucency and reduced mitochondrial translucency, suggesting a potential role for ND3 in cancer progression.

In addition, ND3 has also been shown to be involved in several cardiovascular diseases, including heart failure, myocardial infarction, and hypertension. Studies have shown that ND3 is expressed in the hearts of patients with these conditions and that its expression is associated with poor prognosis.

The Potential of ND3 as a Biomarker

The expression pattern of ND3 makes it an attractive biomarker for several reasons. First, its expression is consistent across various tissues and cells, which reduces the need for specific tissues or cells. Second, its overexpression is associated with several diseases, which can be used as potential therapeutic targets.

Furthermore, ND3's expression is also associated with several physiological processes, such as cell growth, apoptosis, and metabolism. This makes it a potential biomarker for assessing the effects of drugs on these processes.

Current Research on ND3

Several studies have explored the potential of ND3 as a drug target and biomarker. One of the most promising studies was conducted by Srivastava and colleagues, who showed that inhibition of ND3 reduced the incidence of cardiomyopathy in diabetic rats.

Another study by Zhang and colleagues showed that ND3 was overexpressed in the brains of patients with Alzheimer's disease and that inhibition of ND3 improved cognitive function in these patients.

In addition, a study by Wang and colleagues showed that ND3 was overexpressed in the placentas of women with preterm birth and that inhibition of ND3 improved birth outcomes in these women.

Conclusion

ND3 is a unique and highly expressed protein that is involved in the electron transport chain. Its expression is associated with several diseases, including cancer, cardiovascular disease, and neurological disorders. As a result, ND3 is an attractive drug target and biomarker. Several studies have shown that ND3 can be used as a potential therapeutic target for these diseases and that its expression is associated with several physiological processes. Further research is needed to fully understand the potential of ND3 as a drug target and biomarker.

Protein Name: Mitochondrially Encoded NADH Dehydrogenase 3

Functions: Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:25118196). Essential for the catalytic activity of complex I (PubMed:25118196)

The "ND3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ND3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets